Pfizer enters into agreement with AstraZeneca to acquire Neksium brand

01 Jun 2017 Evaluate

Pfizer has entered into an acquisition agreement with AstraZeneca AB, Sweden (AstraZeneca), pursuant to which the brand ‘Neksium’ is being acquired by the company in India for a consideration of Rs 75 crore, subject to completion of necessary conditions precedent. Neksium (esomeprazole) complements the company’s existing product portfolio in the gastrointestinal (GI) therapeutic area. 

Earlier in January, the company had entered into a Delegation of Authority with AstraZeneca Pharma India, pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.



Pfizer Share Price

4777.10 -53.55 (-1.11%)
20-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1470.45
Dr. Reddys Lab 5973.00
Cipla 1547.95
Zydus Lifesciences 1090.00
Lupin 1555.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.